Retatrutide
Next-gen triple agonist (GLP-1 / GIP / glucagon) studied for appetite suppression and fat-loss research.
Recon & Dosing
Open the calculator for Retatrutide vials.
- Category
- Metabolic / GLP-1
- Half-life
- ~6 days
- Typical vial
- 10 mg lyophilised
- Reported research dose
- 1–12 mg weekly in published trial arms
Mechanism of action
Simultaneously activates GLP-1, GIP and glucagon receptors, combining appetite suppression with increased energy expenditure.
Storage & handling
Lyophilised: 2–8 °C. Reconstituted: 2–8 °C, use within 28 days.
Run the reconstitution math →Research notes
- Phase 2 data reported the largest mean weight reduction of any incretin studied to date.
- Titration schedules in trials escalated slowly to limit GI events.
Research use only. Figures above summarise published literature and community protocols for reference. Nothing here is a recommendation for human use.